Home
BMY
BMY News

Latest Bristol-Myers Squibb Company (BMY) News on July 2, 2025

Are Options Traders Betting on a Big Move in Bristol-Myers Squibb Stock?

Zacks

2 days ago

Are Options Traders Betting on a Big Move in Bristol-Myers Squibb Stock?

BMY Loses 16.3% YTD: Should You Buy, Sell or Hold the Stock?

Zacks

2 days ago

BMY Loses 16.3% YTD: Should You Buy, Sell or Hold the Stock?

Jim Cramer Highlights That Incyte’s New CEO is an “Industry Veteran”

Insider Monkey

2 days ago

Jim Cramer Highlights That Incyte’s New CEO is an “Industry Veteran”

AbbVie to buy Capstan for up to $2.1 billion in immunology push

Reuters

2 days ago

AbbVie to buy Capstan for up to $2.1 billion in immunology push

FDA approves label updates for BMS’ CAR T cell therapies

Pharmaceutical Technology

5 days ago

FDA approves label updates for BMS’ CAR T cell therapies

MT Newswires

5 days ago

Bristol-Myers Squibb Gets FDA Approval to Streamline Patient Monitoring, Risk Mitigation for Cancer Therapies

Sickle Cell Disease Treatment Market Analysis and Forecast, 2025-2035 | Intensifying Competition as Key Players Advance Gene and Novel Therapies

GlobeNewswire

5 days ago

Sickle Cell Disease Treatment Market Analysis and Forecast, 2025-2035 | Intensifying Competition as Key Players Advance Gene and Novel Therapies

U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels

Business Wire

5 days ago

U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels

Incyte's New CEO Is A Dealmaking Machine. Will He Bring That Fervor To His New Role?

Investor's Business Daily

6 days ago

Incyte's New CEO Is A Dealmaking Machine. Will He Bring That Fervor To His New Role?

Will MRK's Growing Pipeline Help Navigate the Looming Keytruda LOE?

Zacks

6 days ago

Will MRK's Growing Pipeline Help Navigate the Looming Keytruda LOE?

Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes

Investor's Business Daily

6 days ago

Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes

Incyte replaces CEO Hoppenot with dealmaker Meury

BioPharma Dive

6 days ago

Incyte replaces CEO Hoppenot with dealmaker Meury

Cantor Maintains PriceTarget on BMY, Eyes Alzheimer’s Trial as Key Catalyst

Insider Monkey

7 days ago

Cantor Maintains PriceTarget on BMY, Eyes Alzheimer’s Trial as Key Catalyst

Will New Drugs Enable BMY to Offset the Impact of Generic Competition?

Zacks

7 days ago

Will New Drugs Enable BMY to Offset the Impact of Generic Competition?

3 Top Dividend Stocks to Maximize Your Retirement Income

Zacks

7 days ago

3 Top Dividend Stocks to Maximize Your Retirement Income

BMY Declares $0.60 Dividend, Extends 95-Year Streak

Insider Monkey

8 days ago

BMY Declares $0.60 Dividend, Extends 95-Year Streak

MT Newswires

8 days ago

Sector Update: Health Care Stocks Advance Late Afternoon

MT Newswires

8 days ago

Sector Update: Health Care

MT Newswires

8 days ago

Cigna Sues Bristol Myers Over Alleged Monopoly on Cancer Drug Pomalyst

EXEL Stock Rises on Positive Data From Colorectal Cancer Study

Zacks

8 days ago

EXEL Stock Rises on Positive Data From Colorectal Cancer Study

Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock

Zacks

8 days ago

Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock

The Top 5 Analyst Questions From Bristol-Myers Squibb’s Q1 Earnings Call

StockStory

12 days ago

The Top 5 Analyst Questions From Bristol-Myers Squibb’s Q1 Earnings Call

Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?

Zacks

12 days ago

Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?

Pfizer Boasts Strong Oncology Portfolio: Can it Sustain Growth?

Zacks

13 days ago

Pfizer Boasts Strong Oncology Portfolio: Can it Sustain Growth?

How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks

Zacks

13 days ago

How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks

Q1 Rundown: Royalty Pharma (NASDAQ:RPRX) Vs Other Branded Pharmaceuticals Stocks

StockStory

13 days ago

Q1 Rundown: Royalty Pharma (NASDAQ:RPRX) Vs Other Branded Pharmaceuticals Stocks

Bristol-Myers Squibb (NYSE:BMY) Declares US$0.62 Common and US$0.50 Preferred Dividends

Simply Wall St.

14 days ago

Bristol-Myers Squibb (NYSE:BMY) Declares US$0.62 Common and US$0.50 Preferred Dividends

Trump administration weighs crackdown on pharma ads, Bloomberg says

TipRanks

14 days ago

Trump administration weighs crackdown on pharma ads, Bloomberg says

Bristol Myers Squibb Announces Dividend

Business Wire

15 days ago

Bristol Myers Squibb Announces Dividend

Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly

Zacks

15 days ago

Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly

MT Newswires

15 days ago

Market Chatter: Trump Administration to Consider Pharma Advertising Crackdown

Bristol Myers Squibb Presents Promising Blood Cancer Drug Data at EHA Congress

Insider Monkey

15 days ago

Bristol Myers Squibb Presents Promising Blood Cancer Drug Data at EHA Congress

Bristol Myers Squibb (BMY) Stock Drops Despite Market Gains: Important Facts to Note

Zacks

16 days ago

Bristol Myers Squibb (BMY) Stock Drops Despite Market Gains: Important Facts to Note

MT Newswires

16 days ago

Bristol-Myers Squibb Says Breyanzi Shows 'Lasting' Response in Marginal Zone Lymphoma Trial

Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)

Business Wire

16 days ago

Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)

2 Beaten-Down Dividend Stocks to Buy Right Now

Motley Fool

16 days ago

2 Beaten-Down Dividend Stocks to Buy Right Now

Senators to propose ban on drug ads to consumers, WSJ reports

TipRanks

19 days ago

Senators to propose ban on drug ads to consumers, WSJ reports

Tariffs Create Most Patriotic Earnings Season Yet as US Firms Pander to Trump

Bloomberg

19 days ago

Tariffs Create Most Patriotic Earnings Season Yet as US Firms Pander to Trump

BMY Focuses on Label Expansion of Drugs: Will This Revive Growth?

Zacks

19 days ago

BMY Focuses on Label Expansion of Drugs: Will This Revive Growth?

BMY Reports Positive Data on Sotyktu From Arthritis Study

Zacks

20 days ago

BMY Reports Positive Data on Sotyktu From Arthritis Study

Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025

Business Wire

20 days ago

Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025

Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025

Business Wire

20 days ago

Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025

Bristol-Myers Squibb (NYSE:BMY) Reports Positive Phase 3 Trial Results For Sotyktu

Simply Wall St.

21 days ago

Bristol-Myers Squibb (NYSE:BMY) Reports Positive Phase 3 Trial Results For Sotyktu

MT Newswires

21 days ago

Bristol-Myers Squibb's Sotyktu to Treat Psoriatic Arthritis Meets Primary Goal

Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel

TipRanks

21 days ago

Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Zacks

21 days ago

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know

Zacks

21 days ago

Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know

Bristol Myers bolsters radiopharma portfolio with PhiloChem deal

BioPharma Dive

21 days ago

Bristol Myers bolsters radiopharma portfolio with PhiloChem deal

Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis

Business Wire

21 days ago

Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis

MT Newswires

21 days ago

Bristol-Myers Squibb Unit Enters License for Prostate Cancer Drug Candidate Rights

Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties

GlobeNewswire

22 days ago

Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties

Bristol Myers Squibb (BMY) Exceeds Market Returns: Some Facts to Consider

Zacks

23 days ago

Bristol Myers Squibb (BMY) Exceeds Market Returns: Some Facts to Consider

Bristol Myers Squibb (BMY) is a Top-Ranked Momentum Stock: Should You Buy?

Zacks

23 days ago

Bristol Myers Squibb (BMY) is a Top-Ranked Momentum Stock: Should You Buy?

Acquisitions, Licensing Deals Take Centerstage in Pharma/Biotech Space

Zacks

23 days ago

Acquisitions, Licensing Deals Take Centerstage in Pharma/Biotech Space

3 Stocks With Mouthwatering Dividends You Can Buy Right Now

Motley Fool

24 days ago

3 Stocks With Mouthwatering Dividends You Can Buy Right Now

Patents and economies of scale support Pfizer's wide moat

GuruFocus.com

25 days ago

Patents and economies of scale support Pfizer's wide moat

Markey Researchers Awarded $6.8 Million To Help Others Replicate Kentucky's Lung Cancer Screening Success

ACCESS Newswire

a month ago

Markey Researchers Awarded $6.8 Million To Help Others Replicate Kentucky's Lung Cancer Screening Success

Was Jim Cramer Right About Bristol-Myers Squibb Co. (BMY)?

Insider Monkey

a month ago

Was Jim Cramer Right About Bristol-Myers Squibb Co. (BMY)?

BMY Collaborates for Oncology Drug: Will This Boost Its Portfolio?

Zacks

a month ago

BMY Collaborates for Oncology Drug: Will This Boost Its Portfolio?

Branded Pharmaceuticals Stocks Q1 In Review: Collegium Pharmaceutical (NASDAQ:COLL) Vs Peers

StockStory

a month ago

Branded Pharmaceuticals Stocks Q1 In Review: Collegium Pharmaceutical (NASDAQ:COLL) Vs Peers

Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue?

Zacks

a month ago

Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue?

1 Cash-Producing Stock to Own for Decades and 2 to Think Twice About

StockStory

a month ago

1 Cash-Producing Stock to Own for Decades and 2 to Think Twice About

Bristol-Myers Squibb (NYSE:BMY) Collaborates With BioNTech For Antibody Development In Cancer Treatment

Simply Wall St.

a month ago

Bristol-Myers Squibb (NYSE:BMY) Collaborates With BioNTech For Antibody Development In Cancer Treatment

Bristol Myers Collaborates With BNTX for Oncology Candidate

Zacks

a month ago

Bristol Myers Collaborates With BNTX for Oncology Candidate

Trump’s Tax Bill Is Testing the Dollar. This Red Flag Matters More.

Barrons.com

a month ago

Trump’s Tax Bill Is Testing the Dollar. This Red Flag Matters More.

Bristol Myers Paying BioNTech Up to $11.1B in Cancer Drug Team-up

The Daily Upside

a month ago

Bristol Myers Paying BioNTech Up to $11.1B in Cancer Drug Team-up

Why BioNTech SE (BNTX) Skyrocketed On Monday

Insider Monkey

a month ago

Why BioNTech SE (BNTX) Skyrocketed On Monday

Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing

Zacks

a month ago

Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing

BioNTech Gains 20% On $11.1 Billion Bristol Deal

GuruFocus.com

a month ago

BioNTech Gains 20% On $11.1 Billion Bristol Deal

Bristol to Pay BioNTech Up to $11.1 Billion in Cancer Deal

Bloomberg

a month ago

Bristol to Pay BioNTech Up to $11.1 Billion in Cancer Deal

Investing.com

a month ago

BioNTech soars 15% on cancer drug deal with Bristol Myers

BioNTech Sets Cancer-Drug Deal With Bristol Myers Squibb

The Wall Street Journal

a month ago

BioNTech Sets Cancer-Drug Deal With Bristol Myers Squibb

MT Newswires

a month ago

BioNTech, Bristol Myers Squibb to Co-Develop Bispecific Cancer Treatment

Investing.com

a month ago

BioNTech and Bristol Myers Squibb enter up to $11.1B cancer drug collaboration

BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types

Business Wire

a month ago

BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types

Bristol Myers allies with BioNTech on bispecific cancer drug

BioPharma Dive

a month ago

Bristol Myers allies with BioNTech on bispecific cancer drug

Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Pfizer (NYSE:PFE)

StockStory

a month ago

Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Pfizer (NYSE:PFE)

A Closer Look At Bristol-Myers Squibb Company's (NYSE:BMY) Impressive ROE

Simply Wall St.

a month ago

A Closer Look At Bristol-Myers Squibb Company's (NYSE:BMY) Impressive ROE

Morningstar Research

a month ago

Analyst Report: Bristol-Myers Squibb Company

MT Newswires

a month ago

Meitheal Launches Generic Form of Bristol-Myers Squibb's Abraxane in US

Bristol CEO: Pharma Tariffs Must Not Jeopardize Medicine Supplies

The Wall Street Journal

a month ago

Bristol CEO: Pharma Tariffs Must Not Jeopardize Medicine Supplies

BMY's Opdivo SC Gets EU Nod for Multiple Solid Tumor Indications

Zacks

a month ago

BMY's Opdivo SC Gets EU Nod for Multiple Solid Tumor Indications

Bristol Myers Loses 20.7% in 3 Months: Buy, Sell or Hold the Stock?

Zacks

a month ago

Bristol Myers Loses 20.7% in 3 Months: Buy, Sell or Hold the Stock?

EC approves BMS’ nivolumab SC formulation for solid tumours

Pharmaceutical Technology

a month ago

EC approves BMS’ nivolumab SC formulation for solid tumours

1 S&P 500 Stock for Long-Term Investors and 2 to Brush Off

StockStory

a month ago

1 S&P 500 Stock for Long-Term Investors and 2 to Brush Off

MT Newswires

a month ago

Update: Bristol Myers Squibb, Halozyme Get EC Approval for Subcutaneous Formulation of Opdivo

Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It

Zacks

a month ago

Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It

MT Newswires

a month ago

Bristol Myers Squibb Gets EC Approval for Subcutaneous Formulation of Opdivo

Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Business Wire

a month ago

Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications

Business Wire

a month ago

Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications

MT Newswires

a month ago

Berenberg Adjusts Price Target on Bristol-Myers Squibb to $55 From $60, Maintains Hold Rating

Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down

Zacks

a month ago

Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down

Bristol Myers Squibb (BMY) is a Top-Ranked Value Stock: Should You Buy?

Zacks

a month ago

Bristol Myers Squibb (BMY) is a Top-Ranked Value Stock: Should You Buy?

Bristol-Myers Squibb (NYSE:BMY) Showcases Breakthrough Oncology Data at ASCO 2025 Meeting

Simply Wall St.

a month ago

Bristol-Myers Squibb (NYSE:BMY) Showcases Breakthrough Oncology Data at ASCO 2025 Meeting

EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort

Zacks

a month ago

EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort

With 81% ownership, Bristol-Myers Squibb Company (NYSE:BMY) boasts of strong institutional backing

Simply Wall St.

a month ago

With 81% ownership, Bristol-Myers Squibb Company (NYSE:BMY) boasts of strong institutional backing

Bristol Myers Squibb to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline

Business Wire

a month ago

Bristol Myers Squibb to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline

StockStory

a month ago

1 Safe-and-Steady Stock to Own for Decades and 2 to Think Twice About

Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Corcept (NASDAQ:CORT)

StockStory

a month ago

Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Corcept (NASDAQ:CORT)

Bristol Myers Squibb to Participate in the Bernstein 41st Annual Strategic Decisions Conference

Business Wire

a month ago

Bristol Myers Squibb to Participate in the Bernstein 41st Annual Strategic Decisions Conference

Share on Social Networks: